Trial Search Results

Intranasal Bevacizumab for HHT-Related Epistaxis

This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis when used in conjunction with bipolar electrocautery.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Bevacizumab
  • Drug: Placebo (Saline)


Phase 4


Inclusion Criteria:

   1. The patient carries a diagnosis of hereditary hemorrhagic telangiectasia (HHT)

   2. The patient is to undergo treatment with electrocautery in the operating room under
   endoscopic visualization

   3. The patient is able to give informed consent

   4. The patient is at least 18 years old

Exclusion Criteria:

   1. The patient has had prior treatment with systemic or nasal bevacizumab within the past

   2. The patient has undergone electrocautery for epistaxis within the 6 months prior to
   study enrollment

   3. The patient is a minor

   4. The patient is pregnant

   5. The patient is incapable of understanding the consent process

   6. The patient has a history of HIV or another known cause of immunosuppression, or is
   actively taking immunosuppressive medications due to organ transplantation, rheumatoid
   disease, or other medical conditions.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amelia K Clark, MD